Literature DB >> 15318986

Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight.

Bruno Zilberstein1, Denis Pajecki, Alex Cleiton Garcia de Brito, Samuel Terra Gallafrio, Rony Eshkenazy, Carla Granja Andrade.   

Abstract

BACKGROUND: About 15% of patients who undergo adjustable gastric banding (AGB) have difficulty losing weight due to, among other factors, the development or maintenance of binge eating disorder. Topiramate is an anticonvulsive drug with proven good results in controlling binge eating episodes. The objective of this study was to analyze the effect of topiramate in patients with AGB.
METHODS: 16 patients with binge eating and inadequate weight loss after AGB were analyzed prospectively for 3 months while receiving topiramate in doses varying from 12.5 to 50 mg per day.
RESULTS: There was a mean increase in excess weight loss from 20.4% to 34.1% without the need for band readjustment. 2 patients had intolerance to topiramate and were changed to fluoxetine 40 mg per day.
CONCLUSION: Topiramate may be a useful adjuvant for patients with AGB and binge eating disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15318986     DOI: 10.1381/0960892041590926

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  14 in total

1.  Letter to "Pharmacotherapy in conjunction with diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review".

Authors:  Denis Pajecki; Marco Aurelio Santo; Marcio Correa Mancini
Journal:  Obes Surg       Date:  2016-06       Impact factor: 4.129

2.  The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.

Authors:  Fatima Cody Stanford; Nasreen Alfaris; Gricelda Gomez; Elizabeth T Ricks; Alpana P Shukla; Kathleen E Corey; Janey S Pratt; Alfons Pomp; Francesco Rubino; Louis J Aronne
Journal:  Surg Obes Relat Dis       Date:  2016-10-27       Impact factor: 4.734

3.  The Mitigating Effect of Phentermine and Topiramate on Weight Regain After Roux-en-Y Gastric Bypass Surgery.

Authors:  Nawfal W Istfan; Wendy A Anderson; Donald T Hess; Liqun Yu; Brian Carmine; Caroline M Apovian
Journal:  Obesity (Silver Spring)       Date:  2020-06       Impact factor: 5.002

Review 4.  Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery.

Authors:  Alexis C Sudlow; Carel W le Roux; Dimitri J Pournaras
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

Review 5.  Controversial issues: A practical guide to the use of weight loss medications after bariatric surgery for weight regain or inadequate weight loss.

Authors:  Fatima Cody Stanford
Journal:  Surg Obes Relat Dis       Date:  2018-10-30       Impact factor: 4.734

Review 6.  Role of antiepileptic drugs in the management of eating disorders.

Authors:  Susan L McElroy; Anna I Guerdjikova; Brian Martens; Paul E Keck; Harrison G Pope; James I Hudson
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 7.  Weight Regain After Bariatric Surgery: Prevalence, Etiology, and Treatment.

Authors:  Saketh R Velapati; Meera Shah; Aravind R Kuchkuntla; Barham Abu-Dayyeh; Karen Grothe; Ryan T Hurt; Manpreet S Mundi
Journal:  Curr Nutr Rep       Date:  2018-12

8.  Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features.

Authors:  Mikail Nourredine; Lucie Jurek; Bernard Angerville; Yannick Longuet; Julia de Ternay; Alain Derveaux; Benjamin Rolland
Journal:  CNS Drugs       Date:  2021-02-16       Impact factor: 5.749

9.  Treatment of obese patients with binge eating disorder using topiramate: a review.

Authors:  Paolo Leombruni; Luca Lavagnino; Secondo Fassino
Journal:  Neuropsychiatr Dis Treat       Date:  2009       Impact factor: 2.570

Review 10.  The limits and challenges of antiobesity pharmacotherapy.

Authors:  Kishore M Gadde; Katelyn D Atkins
Journal:  Expert Opin Pharmacother       Date:  2020-04-15       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.